When determining frontline treatment for NSCLC, would you incorporate molecular predictors of resistance to immunotherapy such as STK11, KEAP1, p53?   

This is a great question and there are a number of first line trials that I hope will be able to answer this. I do believe that we should be evaluating these patients specifically for trials (i.e., NCT04265534). I also think looking at these data across the current studies including CM227 and 9LA wi...

While these factors may be important in prognostication, at this time, I do not use these biomarkers to decide upon frontline treatment. I think where these markers become important is in monitoring the patients on treatment. For example, knowing that a patient has these markers of resistance, may p...